Consideration of comorbidity in cancer treatment decision-making in multidisciplinary team meetings
the ONA take:
Comorbidity is very common among patients with cancer. Yet little is known about how comorbidity is factored into treatment decision making for these patients.
Treatment decisions are increasingly made within the context of multidisciplinary team meetings (MDTs). A systematic literature review was conducted to determine if and how comorbidity influences MDT decision-making.
The review included 21 original studies. Findings demonstrate that a lack of information on comorbidity impedes the ability to make treatment recommendations as well as to implement those recommendations.
Adjustments to recommended treatment due to comorbidity tends to result in a more conservative approach, despite evidence that treatments are tolerated and effective.
The review concludes that further research is needed to assist MDTs in appropriately addressing comorbidity in their treatment decisions, which can improve outcomes for cancer patients with comorbidities.
Little is known about how comorbidity is factored into treatment decision making for these patients.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Patients With Urologic Cancer Need Psycho-oncologic Support to Manage High Stress
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|